Disclaimer: This content is for educational purposes only and is not a substitute for medical advice. This is an FDA-approved prescription medication. Consult your healthcare provider before starting, stopping, or changing any treatment.
What PT-141 (Bremelanotide) Is and What It’s Approved For
PT-141, also called bremelanotide, is a melanocortin receptor agonist that acts on brain pathways involved in sexual desire. Unlike PDE5 inhibitors that affect blood flow, it works centrally through the melanocortin system.
It is FDA-approved as a prescription autoinjector (Vyleesi) specifically for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, used on demand. It is not approved for men, not approved for enhancing sexual performance, and not indicated for broader libido concerns outside the labeled population. This page covers its mechanism, dosing, side effects, and regulatory status.
What Is PT-141, Exactly?
PT-141, also called bremelanotide, is a synthetic cyclic heptapeptide that mimics the body’s melanocortin signaling. Chemically, it carries the ACTH(4–10) motif and was derived from melanotan II toward selectivity at the melanocortin-4 receptor (MC4R).
In the United States, PT-141 is FDA-approved as a prescription autoinjector — Vyleesi — for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, used on demand. It’s not approved for men or for conditions outside HSDD. Intranasal versions were studied but are not FDA-approved.
Understanding what PT-141 is approved for is one thing — understanding why it works requires a closer look at its mechanism of action.
How PT-141 Works in the Body
Plain language first: PT-141 activates melanocortin receptors in the brain, especially MC4R, in regions like the hypothalamus that help coordinate motivation, reward, and sexual behavior. That central activation can shift neural tone around desire, acting more like a conductor than the brass section.
Mechanistically, PT-141 engages the melanocortin system with clinically relevant activity at MC4R and crosstalk with dopamine pathways. That’s the key difference from PDE5 inhibitors. Viagra-type drugs improve genital blood flow via nitric oxide; PT-141 works upstream in the central nervous system to influence desire.
In Phase 3 RECONNECT trials for women with HSDD, PT-141 was associated with increased sexual desire and reduced distress versus placebo within an on-demand window. Early studies in men with erectile dysfunction were inconsistent, and the drug is not approved for that use.
For those prescribed PT-141 within its approved indication, proper dosing and administration are essential to both efficacy and safety.
Dosage and Administration Essentials
PT-141 is taken as needed, not daily. The FDA-approved dose is 1.75 mg via subcutaneous autoinjector, typically in the abdomen or thigh. Administer at least 45 minutes before anticipated sexual activity; onset often lands within about an hour and can last several hours. Use is limited to no more than one dose in 24 hours and no more than eight doses per month, a cap established in the FDA-approved labeling.
Non-approved forms (like intranasal sprays or compounded vials) circulate online. Absorption and potency vary, and these products lack regulatory oversight for quality or safety.
Regardless of source, anyone considering PT-141 should understand its well-documented safety profile.
Safety, Side Effects, and Contraindications
The safety profile is well described from the approval program. Nausea is the standout side effect, most often early in use. PT-141 can cause temporary increases in blood pressure and small drops in heart rate for several hours after a dose. Flushing, headache, and injection site reactions are common. Focal hyperpigmentation — dark patches on the face, gums, or skin — can occur with more frequent dosing and may persist.
Numbers help anchor expectations: nausea (~40%), flushing (~20%), injection-site reactions (~13%), headache (~11%). Transient systolic blood pressure rises peak at about 6 mm Hg and resolve within 12 hours. Recent phase 4 and post-marketing data suggest blood pressure effects remain stable with labeled, on-demand use.
PT-141 slows gastric emptying, which can reduce exposure to some oral drugs. Oral naltrexone is the clearest interaction in labeling and should not be taken alongside PT-141. Safety in pregnancy and breastfeeding is not established. People with uncontrolled hypertension or known cardiovascular disease are advised to avoid PT-141 because of its blood pressure effects. Severe renal impairment or significant liver disease can increase exposure and were underrepresented in trials.
Common effects to know
- Nausea, vomiting, flushing, headache
- Temporary rise in blood pressure and mild heart-rate drop
- Injection site reactions
- Focal hyperpigmentation (skin or gums)
- Worsening nausea with more frequent use
Short term, most effects are transient; longer-term data are more limited outside the approved indication.
Where PT-141 Fits Among Peptides
Peptides differ by receptor targets and tissue focus. PT-141 sits in the melanocortin family, where receptor selectivity shapes outcomes.
Melanotan II leans harder on MC1R, with stronger pigment effects and no FDA approval for sexual function. PT-141 was engineered toward desire with an on-demand clinical profile. Oxytocin relates more to social salience and bonding; intranasal formulations show mixed results for sexual function and are not approved for HSDD. Kisspeptin drives GnRH and reproductive-axis signaling; early human data hint at pro-sexual effects, but it remains research-stage for desire disorders.
“Stacking” comes up a lot. Pairing a central desire modulator with a peripheral blood-flow agent has mechanistic logic, yet combination strategies aren’t standardized or broadly approved.
Before exploring any peptide regimen, it helps to understand the current legal and regulatory landscape surrounding PT-141.
Legal Status and Regulatory Overview
In the U.S., bremelanotide is FDA-approved as a prescription autoinjector (Vyleesi) for acquired, generalized HSDD in premenopausal women. That means lot-tested purity, known dosing, and a defined label. Compounded or gray-market products (sprays, vials, lozenges) are not FDA-approved and may vary in potency or contain impurities.
Rules differ internationally but follow the same theme: narrow labeled indications and variable quality outside them. For competitive athletes, WADA’s S0 category prohibits non-approved substances, which can include some peptides sold outside regulatory channels. If eligibility matters, check the current WADA Prohibited List rather than assuming.
Quality and consistency matter with peptides.
Summary
Bremelanotide (PT-141) is a melanocortin receptor agonist FDA-approved for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women (Vyleesi, FDA-approved 2019). It is used on demand at 1.75 mg subcutaneously, capped at one dose per day and eight per month. It is not approved for men, not indicated for enhancing sexual performance, and not approved for broader libido concerns outside the labeled population. Nausea is the most common side effect; blood pressure can rise transiently, and pigmentation changes can occur with frequent use. Patients considering this medication should discuss appropriateness, contraindications, and monitoring with a licensed clinician.
Regulatory and Availability Status
- Regulatory Status: FDA-approved for acquired, generalized hypoactive sexual desire disorder in premenopausal women (Vyleesi, FDA-approved 2019). Not approved for men or for broader sexual function indications.
- Research Stage: Approved and marketed for specific indication
- Availability: Prescription only
Disclaimer: This content is for educational purposes only and is not a substitute for medical advice. This is an FDA-approved prescription medication. Consult your healthcare provider before starting, stopping, or changing any treatment.
.svg)
.avif)